Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Icecure Medical Ltd - SIC # 3845 - ELECTROMEDICAL AND ELECTROTHERAPEUTIC APPARATUS
Ticker
Exchange
SIC #
Website
Latest Ticker
ICCM
Nasdaq
3845
https://icecure-medical.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Icecure Medical Ltd
IceCure Medical (ICCM) Submits Final Cryoablation Data to FDA
- Apr 18th, 2024 3:07 pm
IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer
- Apr 15th, 2024 12:35 pm
IceCure Medical Ltd (NASDAQ:ICCM) Q4 2023 Earnings Call Transcript
- Apr 4th, 2024 1:28 pm
IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance
- Apr 3rd, 2024 12:30 pm
IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes
- Apr 2nd, 2024 12:30 pm
IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024
- Mar 27th, 2024 12:30 pm
IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy
- Mar 19th, 2024 12:30 pm
IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes
- Mar 12th, 2024 12:30 pm
IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference
- Mar 7th, 2024 1:30 pm
IceCure's ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024
- Mar 4th, 2024 1:30 pm
Fourth BRIIT Conference in India Features IceCure's ProSense® in Breast Cancer Imaging & Interventions Workshop
- Feb 27th, 2024 1:00 pm
Study Using IceCure's ProSense® Treatment Results in 100% Tumor Reduction in Early-Stage Breast Cancer
- Feb 26th, 2024 1:00 pm
IceCure's ProSense® to be Featured at Two Upcoming Medical Conferences in Japan
- Feb 15th, 2024 1:00 pm
U.S. FDA Grants IceCure Medical's Appeal: Reopens De Novo Classification Request for Marketing Authorization of ProSense® for Early-Stage Breast Cancer
- Jan 30th, 2024 1:00 pm
IceCure Medical's Breast Cryoablation Gains Prominence in the U.S., as Society of Interventional Oncology Annual Meeting Features its First Breast Cryoablation Master Class
- Jan 29th, 2024 1:00 pm
IceCure Medical's ProSense® Featured at Indian Society of Vascular and Interventional Radiology Conference: Key Opinion Leaders Highlight Benefits of Cryoablation
- Jan 16th, 2024 1:00 pm
IceCure Medical Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
- Jan 12th, 2024 9:05 pm
IceCure Medical CEO Issues Letter to Shareholders & Reports Increase in Sales in Preliminary Unaudited 2023 Results
- Jan 10th, 2024 1:00 pm
New Study Reports IceCure's ProSense® Boosts Immune Response Against Cancer: Enhances CD8+ T Cell Response
- Jan 3rd, 2024 1:00 pm
Study Using IceCure's ProSense® Finds: "Cryoablation Allows the Ultimate De-escalation of Surgical Therapy for Select Breast Cancer Patients"
- Dec 13th, 2023 1:00 pm
Scroll